98%
921
2 minutes
20
To make optimal decisions in uncertain circumstances flexible adaption of behaviour is required; exploring alternatives when the best choice is unknown, exploiting what is known when that is best. Using a computational model of the basal ganglia, we propose that switches between exploratory and exploitative decisions are mediated by the interaction between tonic dopamine and cortical input to the basal ganglia. We show that a biologically detailed action selection circuit model, endowed with dopamine dependant striatal plasticity, can optimally solve the explore-exploit problem, estimating the true underlying state of a noisy Gaussian diffusion process. Critical to the model's performance was a fluctuating level of tonic dopamine which increased under conditions of uncertainty. With an optimal range of tonic dopamine, explore-exploit decisions were mediated by the effects of tonic dopamine on the precision of the model action selection mechanism. Under conditions of uncertain reward pay-out, the model's reduced selectivity allowed disinhibition of multiple alternative actions to be explored at random. Conversely, when uncertainly about reward pay-out was low, enhanced selectivity of the action selection circuit facilitated exploitation of the high value choice. Model performance was at the level of a Kalman filter which provides an optimal solution for the task. These simulations support the idea that this subcortical neural circuit may have evolved to facilitate decision making in non-stationary reward environments. The model generates several experimental predictions with relevance to abnormal decision making in neuropsychiatric and neurological disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neuroscience.2021.05.010 | DOI Listing |
Br J Pharmacol
September 2025
Division of Pharmaceutical Sciences, University of Cincinnati, James L. Winkle College of Pharmacy, Cincinnati, Ohio, USA.
Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment-resistant depression because of their ability to alter consciousness and afflicted cognitive processes with lasting effects. We aimed to characterise how psychedelics are currently being investigated to treat substance use disorders (SUDs). Additionally, we aimed to summarise the available literature on the dopaminergic consequences of classic psychedelics in the nucleus accumbens (NAc), a foundational component of SUDs, to understand how psychedelics may be therapeutically relevant for SUDs from a neurobiological perspective.
View Article and Find Full Text PDFAnn Neurol
August 2025
Clinical Investigation Center CIC1436, Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Centre and NeuroToul Center of Excellence in Neurodegeneration (COEN) of Toulouse; INSERM, University of Toulouse, CHU of Toulouse, Toulouse, France.
Objective: The objective of this study was to characterize changes in candidate biomarkers in early multiple system atrophy (MSA) and identify baseline predictors of faster progression.
Methods: This 1-year, multicenter, prospective study assessed clinical, neuroimaging (3T-magnetic resonance imaging [MRI], dopamine transporter single-photon emission computed tomography [DaT-SPECT]), and neurofilament light chain (NfL) changes in patients with early MSA (< 5 years from symptom onset) and healthy controls (HCs). Clinical and biomarker changes from baseline to 6 months (M6) and 12 months (M12) were analyzed.
J Affect Disord
August 2025
Lab of Stereotaxy and Interventional Neurosciences (SIN), Dept. of Stereotactic and Functional Neurosurgery, Medical Center - University of Freiburg, Germany; Dept. of Stereotactic and Functional Neurosurgery, Medical Center - University of Freiburg, Germany; Faculty of Biology, University of Freibu
Background: Superolateral medial forebrain bundle (mfb) DBS has shown rapid and lasting antidepressant effects in treatment-resistant depression (TRD). Diverse stimulation parameters recruit the unmyelinated dopaminergic (DA) or the other myelinated mfb projections differently and with variable effects on the reward circuitry. Prior studies have demonstrated acute differences in DA release across depressive and healthy models with varying pulse widths (PWs).
View Article and Find Full Text PDFbioRxiv
August 2025
Department of Psychology, University of Memphis, Memphis, TN.
Deficits in social behavior, such as reduced motivation and social avoidance, are key symptoms in several psychiatric disorders. Distinct modes of reward, such as drug and social, may rely on different dopamine release patterns in the mesolimbic pathway. We investigated the relationship between social reward behaviors and dopamine release elicited by phasic and tonic stimulation patterns in C57BL/6J mice.
View Article and Find Full Text PDFCommun Biol
August 2025
MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK.
Noradrenaline plays an integral role in learning by optimising behavioural strategies and facilitating choice execution. Testing the noradrenergic framework of learning in the context of human diseases offers a test bed for current normative neuroscience theories and may also indicate therapeutic potential. Parkinson's disease is often considered as a model of dopamine deficits, including dopamine's role in reinforcement learning.
View Article and Find Full Text PDF